Literature DB >> 23345462

Liver disease as a cause of thrombocytopenia.

S H Hancox1, B C Smith.   

Abstract

BACKGROUND: Liver disease is frequently missed as the cause for a patient's thrombocytopenia. AIM: To evaluate the role of liver disease in causing thrombocytopenia within a tertiary hospital.
DESIGN: A hospital-based retrospective study.
METHODS: Analysis of medical records of outpatients and inpatients with a platelet count <100 × 10(9)/l seen at St Mary's Hospital, London in October 2011, was conducted. Cause for thrombocytopenia was determined in each case and patients with liver disease were analysed further looking at factors associated with their low platelet count.
RESULTS: In total, 223 patients were included in this study, 109 of them were outpatients and 114 were inpatients. The mean age was 57.1 years (range 22-106), 64% male and 36% female. Liver disease was the cause for thrombocytopenia in 58% of outpatients. Overall, 92 patients with liver disease were identified; cirrhosis and/or splenomegaly were present in 78%, a further 8% were on interferon therapy. Thrombocytopenia was not explained by the extent of liver disease in 8%, significantly more in hepatitis C than other causes of liver disease (P < 0.05). Factors correlating with low platelet count in patients with liver disease were spleen size (P < 0.05) and serum bilirubin (P < 0.001). There were none, or mild abnormalities only in liver function tests in 19 patients with liver disease-associated thrombocytopenia.
CONCLUSION: Liver disease should be considered in all patients with an unknown cause of thrombocytopenia. Advanced liver disease does not have to be present for thrombocytopenia to develop. All patients with unexplained thrombocytopenia should be evaluated to see if liver disease is present, even when liver function tests are normal.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23345462     DOI: 10.1093/qjmed/hcs239

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  6 in total

1.  Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Hind I Fallatah; Hisham O Akbar; Alyaa M Fallatah
Journal:  Hepat Mon       Date:  2016-07-03       Impact factor: 0.660

Review 2.  New-onset acute thrombocytopenia in hospitalized patients: pathophysiology and diagnostic approach.

Authors:  Naveed Ali; Herbert E Auerbach
Journal:  J Community Hosp Intern Med Perspect       Date:  2017-07-13

3.  Longitudinal decrease in platelet counts as a surrogate marker of liver fibrosis.

Authors:  Neta Gotlieb; Naama Schwartz; Shira Zelber-Sagi; Gabriel Chodick; Varda Shalev; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2020-10-14       Impact factor: 5.742

4.  The Effect of TGF-β1 Reduced Functionality on the Expression of Selected Synaptic Proteins and Electrophysiological Parameters: Implications of Changes Observed in Acute Hepatic Encephalopathy.

Authors:  Mariusz Popek; Bartosz Bobula; Karolina Orzeł-Gajowik; Magdalena Zielińska
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

5.  Ultrasonographic assessment of splenic volume and its correlation with body parameters in a Jordanian population.

Authors:  Darwish H Badran; Heba M Kalbouneh; Maher T Al-Hadidi; Amjad T Shatarat; Emad S Tarawneh; Azmy M Hadidy; Waleed S Mahafza
Journal:  Saudi Med J       Date:  2015-08       Impact factor: 1.484

6.  Unconjugated Bilirubin exerts Pro-Apoptotic Effect on Platelets via p38-MAPK activation.

Authors:  Somanathapura K NaveenKumar; Ram M Thushara; Mahalingam S Sundaram; Mahadevappa Hemshekhar; Manoj Paul; Chinnasamy Thirunavukkarasu; Ganesh Nagaraju; Sathees C Raghavan; Kesturu S Girish; Kempaiah Kemparaju; Kanchugarakoppal S Rangappa
Journal:  Sci Rep       Date:  2015-10-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.